2009
DOI: 10.1213/ane.0b013e3181a801b9
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Investigation of Neuraxially Administered Drugs: A Regulatory Perspective

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2009
2009
2017
2017

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 1 publication
0
2
0
Order By: Relevance
“…6,16,17 Another advantage is its selective delivery to the appropriate spinal level. Lipo-PGE1 agonists are expected to be very efficacious when administered to the area directly adjacent to the spinal cord.…”
Section: Discussionmentioning
confidence: 99%
“…6,16,17 Another advantage is its selective delivery to the appropriate spinal level. Lipo-PGE1 agonists are expected to be very efficacious when administered to the area directly adjacent to the spinal cord.…”
Section: Discussionmentioning
confidence: 99%
“…These pathways require continued investigation into neuraxial drug administration. In a separate editorial in this issue of the journal, Schultheis et al 9 from the Food and Drug Administration describe issues involved in the human study of new neuraxial drugs or formulations. Federal regulations require institutional review boards to institute additional safeguards before approving research involving pregnant women and fetuses.…”
mentioning
confidence: 99%